Gene editing: which startup is ahead?
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
CRISPR Therapeutics is the gene-editing startup ahead today, with Intellia close enough to take the lead and Beam established as the strongest next-generation challenger.
The ranking is really a contest between three different kinds of proof. CRISPR Therapeutics has approval and commercial use, Intellia has the best late-stage in vivo evidence, and Beam has shown that base editing can work in two distinct human treatment settings.
CASGEVY gives CRISPR Therapeutics an advantage that goes beyond clinical efficacy. The company and Vertex have already worked through manufacturing, treatment-centre qualification, reimbursement and the messy logistics of getting a patient from referral to infusion.
Intellia has the clearest route to changing the hierarchy. Lonvo-z has completed a randomized Phase 3 trial, entered a rolling US submission and could be easier to scale than a patient-specific stem-cell therapy if approval and launch go cleanly.
Beam’s position is unusually strong for a company without a Phase 3 result. Risto-cel and BEAM-302 support the same core editing platform in blood-forming stem cells and inside the liver, which is harder to dismiss than a single successful asset.
Precision BioSciences shows why patient count alone can mislead. Its hepatitis B study is small, but the liver-biopsy evidence goes straight at cccDNA, the viral reservoir that current drugs usually fail to remove.
Caribou has the deepest gene-edited off-the-shelf CAR-T dataset, yet its lead is fragile. Vispa-cel must carry serious safety questions into a large Phase 3 trial, and the company does not currently have enough cash to fund the whole program comfortably.
Prime Medicine has delivered one of the field’s most striking early results, but two patients are still two patients. Arbor, Scribe and Tessera have crossed or are crossing into human testing, while Metagenomi and Mammoth remain platform stories until therapeutic data arrive.
Capital is not a side issue here. CRISPR Therapeutics and Beam can keep several expensive programs alive at once, while smaller rivals may have to partner, narrow their pipelines or raise money before the decisive trial.
The current order can change quickly, but only at specific milestones: a clean lonvo-z approval and launch, a risto-cel filing, pivotal BEAM-302 execution, durable hepatitis B functional-cure evidence, or convincing first-in-human results from the newer editing systems.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Gene editing: which startup is ahead?
Which gene-editing startups belong in this comparison?
CRISPR Therapeutics, Intellia and Beam form the serious leading group today, while nine smaller companies deserve inclusion because they own distinct editing systems or have already crossed into human testing.
We are comparing 12 independent companies whose main business is building gene-editing medicines for people. That includes public biotechs such as CRISPR Therapeutics, Intellia, Beam and Editas. They may be listed, but they still behave like startups in the ways that matter here: most products are experimental, losses are funded through capital markets, and one clinical setback can change the company’s future.
The field is deliberately broad. CRISPR Therapeutics and Intellia use conventional CRISPR cutting. Beam uses base editing. Prime uses prime editing. Precision has its own ARCUS nuclease. Tessera is developing Gene Writing. Scribe is starting with epigenetic silencing, which turns a gene down without permanently rewriting its DNA sequence. Caribou uses editing to manufacture donor-derived CAR-T cells. Arbor, Metagenomi and Mammoth are trying to solve delivery and size constraints with newer compact editors.
Vertex is excluded because it is a large pharmaceutical company and CRISPR Therapeutics’ commercialization partner. Verve is excluded because Eli Lilly bought it. We also leave out diagnostics, agricultural editing, research-tool companies, xenotransplantation and cell-therapy companies where gene editing plays only a supporting role.
The funding figures below mainly come from Tracxn and represent reported cumulative funding rounds; Scribe’s figure is updated from its recent SEC filing. They show how heavily each company was backed before or around its public listing, but exclude some later stock offerings, debt, grants and partnership payments. Current cash is compared separately.
| Startup | What it is trying to build | Furthest stage today | Reported cumulative funding |
|---|---|---|---|
| CRISPR Therapeutics | CRISPR medicines across blood, autoimmune, cancer and in vivo liver programs | Approved product | $127M |
| Intellia Therapeutics | Systemic in vivo CRISPR medicines delivered mainly to the liver | Phase 3 completed; rolling BLA | $85M |
| Beam Therapeutics | Base-edited cell therapies and in vivo medicines | Phase 1/2; BLA and pivotal plans | $222M |
| Precision BioSciences | ARCUS in vivo editing for viral and genetic diseases | Two clinical programs | $136M |
| Caribou Biosciences | Gene-edited off-the-shelf CAR-T therapies | Phase 1; pivotal design agreed | $157M |
| Prime Medicine | Prime-edited cell and in vivo medicines | First human proof; more trials starting | $315M |
| Arbor Biotechnologies | Compact CRISPR editors for rare genetic diseases | Phase 1/2 | $304M |
| Tessera Therapeutics | Gene Writing for correction and insertion | First clinical study cleared | $610M |
| Scribe Therapeutics | Compact CRISPR editing and epigenetic silencing | First clinical study cleared | About $150M |
| Editas Medicine | In vivo gene editing, now led by a cardiovascular program | Preclinical lead program | $210M |
| Metagenomi Therapeutics | New editors discovered through metagenomics | Preparing first IND | $376M |
| Mammoth Biosciences | Ultracompact editors for harder-to-reach tissues | Preclinical therapeutic programs | $271M |
Is there a clear gene-editing leader today?
CRISPR Therapeutics leads overall, although Intellia is now close enough to threaten that position and Beam has separated from the rest of the field.
The market has one commercial leader, one late-stage in vivo challenger and one next-generation platform with two serious clinical shots. CRISPR Therapeutics co-developed the only approved medicine in this group. Intellia has completed the first successful randomized Phase 3 trial for a treatment that edits genes directly inside the body. Beam has human data from both an edited stem-cell therapy and an in vivo base-editing treatment.
The hierarchy is much sharper than it was even a year ago. CRISPR Therapeutics has completed the full journey from laboratory work to approval, reimbursement and product revenue. Intellia has completed the hardest clinical test before approval. Beam is earlier, but progress across two different products makes it difficult to write off as a one-program story.
Below those three, the market splits into specialists. Precision leads the early hepatitis B race, Caribou has the deepest gene-edited off-the-shelf CAR-T dataset, and Prime has produced the first human proof for prime editing. The remaining companies still need stronger clinical evidence.
If you want more recent data on this point, please see our latest biotechnology market report.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Which gene-editing startup has the strongest clinical evidence?
CRISPR Therapeutics has the strongest clinical evidence across the whole market, while Intellia now owns the best late-stage evidence for in vivo gene editing.
CASGEVY has cleared several regulatory reviews and moved into routine treatment systems for sickle cell disease and transfusion-dependent beta thalassemia. Approval carries more weight than a promising biomarker because regulators have reviewed efficacy, safety, manufacturing and long-term follow-up together. CRISPR Therapeutics has proved that edited cells can be made consistently and delivered outside a controlled trial.
Intellia’s HAELO study is the strongest evidence produced by a challenger. The randomized trial enrolled 80 people with hereditary angioedema. A single lonvo-z infusion reduced mean monthly attacks by 87% versus placebo. It also cut attacks requiring rescue treatment by 89% and moderate or severe attacks by 91%. Sixty-two percent of treated patients went through the six-month efficacy period without an attack or continuing preventive therapy, compared with 11% on placebo.
Beam ranks behind those two, though its evidence is broader than most competitors’. Risto-cel has been studied in 31 people with sickle cell disease, and BEAM-302 has produced direct evidence of corrected protein in people with alpha-1 antitrypsin deficiency. Caribou has treated more patients than Beam in its lead program, but cancer response data are awkward to compare because disease severity, previous therapy and follow-up can change the apparent result. Prime’s result is scientifically striking; a two-patient sample cannot carry the same weight.
Safety also separates the field. CASGEVY carries the risks and logistics of stem-cell transplantation and busulfan conditioning. Lonvo-z has the cleanest randomized in vivo safety package so far, though the serious liver event in Intellia’s separate nex-z program means the wider platform is not fully de-risked.
| Startup | Strongest human evidence | Approximate scale | Our reading |
|---|---|---|---|
| CRISPR Therapeutics | Approved CASGEVY with commercial use | Hundreds in the treatment journey | Deepest total validation |
| Intellia | Positive randomized HAELO Phase 3 trial | 80 randomized patients | Best in vivo evidence |
| Beam | Human proof in sickle cell disease and AATD | 60 patients across the two main datasets | Broadest next-generation proof |
| Caribou | Long-term lymphoma responses with vispa-cel | 85 treated in the wider program | Strong specialist dataset with difficult safety questions |
| Precision | Direct liver-biopsy evidence against HBV cccDNA | 16 patients, 38 administrations | Small study with unusually meaningful biology |
| Prime | Large correction in p47phox CGD | Two patients | Breakthrough proof, far too small for certainty |
Which gene-editing startup is closest to the next approval?
Intellia is the favorite to secure the next important gene-editing approval because lonvo-z has finished Phase 3 and its US application is already being submitted in stages.
The HAELO trial gave Intellia a complete randomized efficacy package rather than another small open-label study. The company began a rolling biologics license application after the trial met its primary and key secondary endpoints, and it has said a US launch could follow in the first half of 2027 if the review goes well. No other independent company in this comparison has reached that combination of completed Phase 3 evidence and an active submission.
Beam is the closest follower. The company says it could submit risto-cel for sickle cell disease as early as the end of 2026. It also plans to start an approximately 50-patient pivotal cohort for BEAM-302 under an accelerated-approval strategy. Both paths still depend on additional execution and regulatory agreement.
Prime is a more distant outsider. The FDA has granted PM359 RMAT designation after strong results in two people with a rare immune disorder, but the dataset is far too small to make Prime the likely next approval.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Which gene-editing startup has built a real business?
CRISPR Therapeutics is the only company in this comparison with a real product business, giving it a commercial lead that no rival can currently measure against.
CASGEVY generated $43 million of revenue in the first quarter of 2026. More than 500 people had started the treatment journey, and roughly 90% of eligible US patients had reimbursed access by the end of 2025. Those figures describe actual demand moving through referrals, cell collection, manufacturing, conditioning and infusion.
The Vertex partnership deserves much of the credit. Vertex leads global development, manufacturing and commercialization, while CRISPR Therapeutics receives 40% of program profits and pays 40% of costs. The arrangement limits CRISPR Therapeutics’ share of the economics, but it also gave CASGEVY a global commercial operation that a young biotech would have struggled to build alone.
Other companies report revenue from licensing, collaborations or milestone payments. Those agreements can validate the technology and finance development, but they do not show that doctors are prescribing a product or that patients are creating repeatable demand.
If you want more recent data on this point, please see our latest biotechnology market report.
Is Intellia the leader in in vivo gene editing now?
Intellia now leads in vivo gene editing because lonvo-z has moved direct editing inside the body from early promise to successful Phase 3 evidence.
Lonvo-z is designed to switch off KLKB1 in liver cells after one infusion and reduce the biological trigger behind hereditary-angioedema attacks. The result is especially convincing because patients already have effective preventive drugs. Intellia had to show enough efficacy and convenience to compete with treatments that already control the disease.
The newest HAELO analysis strengthens that case. Beyond the overall reduction in attacks, Intellia reported an 89% drop in attacks requiring on-demand treatment, a 91% reduction in moderate or severe attacks and a quality-of-life improvement far above the threshold considered clinically meaningful. Three-year follow-up from the earlier study also suggests that the effect can persist.
Beam’s BEAM-302 is the closest next-generation competitor, though it remains in Phase 1/2. Precision has shown that ARCUS can reach and disrupt persistent hepatitis B DNA inside the liver, but its study is still small. Arbor has begun dosing, while Tessera and Scribe are preparing their first human studies.
The nex-z liver-safety episode still hangs over Intellia’s broader platform. Even so, no rival has matched lonvo-z’s late-stage combination of efficacy, tolerability and regulatory progress.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Is Beam becoming the strongest gene-editing platform?
Beam has the strongest next-generation platform today because base editing has now worked in two very different human treatment settings.
Risto-cel edits a patient’s blood-forming stem cells outside the body. In the reported 31-patient dataset, fetal haemoglobin rose above 60% on average, sickle haemoglobin fell below 40%, and severe vaso-occlusive crises stopped after engraftment during the available follow-up. The manufacturing process also required a median of one collection cycle.
BEAM-302 tests a harder proposition: correcting a disease-causing mutation directly inside the liver. At the selected 60-milligram dose, mean total alpha-1 antitrypsin reached 16.1 micromolar, above the 11-micromolar level commonly treated as protective. Corrected M-AAT accounted for 94% of total protein, while harmful Z-AAT fell by 84%.
Together, the programs show that Beam’s editing system can work in manufactured stem cells and through systemic liver delivery. That makes the platform more credible than a pipeline supported by one asset or one tissue.
The FDA has also cleared BEAM-304 for phenylketonuria, and Beam’s $1.2 billion cash position should allow it to pursue risto-cel and BEAM-302 together. Beam remains third because it has no approved product or completed Phase 3 trial.
Is Precision BioSciences the most underrated gene-editing company?
Precision BioSciences is the most underrated clinical challenger because its hepatitis B program has produced direct evidence against the viral reservoir that keeps the infection alive.
Current hepatitis B drugs can suppress viral replication, but they usually leave covalently closed circular DNA, known as cccDNA, inside liver cells. Precision’s PBGENE-HBV is designed to attack that reservoir. In liver-biopsy data presented at the European liver congress, the company reported a tenfold reduction in cccDNA-derived transcripts. Among six patients with detectable pregenomic RNA before treatment, all six became undetectable afterward. Less than 1% of the original cccDNA remained in the biopsy analysis, and edits in the remaining material reportedly disabled viral polymerase.
The sample is small: 16 people had received 38 administrations across several cohorts. The data need longer follow-up, more biopsies and a demonstrated link to durable functional cure. Even with those limits, the result is more informative than a generic fall in a downstream blood marker.
Repeat dosing adds another useful piece of evidence. Many gene-editing programs are built around one administration because immune reactions or delivery toxicity may complicate a second dose. Precision has already accumulated experience across 38 administrations.
The company has also opened enrolment for PBGENE-DMD in Duchenne muscular dystrophy. Its balance sheet is much smaller than those of the top three, but its clinical evidence is strong enough to justify fourth place.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Can Caribou’s gene-edited CAR-T work at commercial scale?
Caribou has built the strongest gene-edited off-the-shelf CAR-T program, but vispa-cel carries enough safety and financing risk to keep the company outside the top four.
Vispa-cel uses donor cells that can be produced in batches and stored, avoiding the patient-by-patient manufacturing delay of conventional autologous CAR-T. In the 27-patient subgroup that best matches Caribou’s planned Phase 3 treatment, the overall response rate was 82%, the complete-response rate was 67%, and median progression-free survival reached 17.1 months.
The safety record is harder. The same subgroup had one treatment-related death from an immune-effector-cell-associated inflammatory syndrome and one death considered possibly related because of progressive multifocal leukoencephalopathy. Severe infections and prolonged low blood-cell counts also occurred.
Caribou has agreed with the FDA on a roughly 250-patient randomized Phase 3 design across about 75 sites. The company ended the first quarter with $118.6 million and said its existing plan covered start-up work rather than the entire pivotal program. That is a lot to ask from a balance sheet this size.
Vispa-cel could move Caribou sharply upward if Phase 3 confirms durable responses with acceptable safety and the company secures full financing.
Has Prime Medicine proved that prime editing works in people?
Prime Medicine has proved that prime editing can create a large biological correction in humans, but the evidence is too small to establish a repeatable platform.
PM359 corrects a mutation in blood-forming stem cells from people with a rare form of chronic granulomatous disease. The first two treated patients reached 69% and 83% DHR-positive neutrophils by day 30. The reference level for expected clinical benefit was 20%, so both patients cleared it by more than threefold. The corrected activity remained stable during the reported follow-up, and the result earned FDA RMAT designation.
Prime editing aims to make precise substitutions, insertions and deletions without relying on the same kind of double-strand DNA cut used by conventional CRISPR. Showing a large correction in long-lived human stem cells moves the technology beyond animal promise.
Two successful patients cannot show how often manufacturing fails, whether editing varies widely, or whether rare safety problems emerge. The therapy also uses stem-cell collection and conditioning, so it says little about Prime’s in vivo liver programs.
Prime is now advancing Wilson disease and AATD programs. We rank it sixth because the first result is exceptional but still narrow.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Which gene-editing startup has the strongest and hardest-to-copy platform?
CRISPR Therapeutics has the broadest mature pipeline, while Beam has the strongest scientific platform that competitors would struggle to copy.
CRISPR Therapeutics now spans an approved blood-disorder product, allogeneic cell therapy, autoimmune disease, oncology, cardiovascular editing, liver-directed correction and regenerative medicine. Some programs use siRNA or cell replacement alongside gene editing, so the company is broader than a pure editor. Even after applying that discount, it has more clinically advanced ways to create value than any rival.
Beam’s pipeline is smaller but more internally consistent. Risto-cel, BEAM-302, BEAM-301 and BEAM-304 all rely on the company’s base-editing and delivery systems. Copying one base-editing enzyme would not reproduce the full system. A rival would need to match guide design, control unwanted edits, reach the correct cells, manufacture the treatment consistently and reproduce the clinical results.
Intellia has built the deepest operating knowledge in systemic in vivo CRISPR. It has taken a treatment from first human dosing through randomized Phase 3, handled a serious safety interruption in another program and worked with regulators to restart development. That experience around dosing, liver monitoring, manufacturing and trial design cannot be licensed overnight.
CRISPR Therapeutics has the strongest commercial moat. Through CASGEVY and Vertex, it has learned how to qualify treatment centres, release patient-specific products, secure reimbursement and operate across several regulatory systems.
Prime and Tessera can describe a wider theoretical editing range, while Scribe, Mammoth, Arbor and Metagenomi may eventually reach tissues or targets that larger CRISPR systems cannot. Those advantages remain mostly unproven in people.
Beam gets the scientific-platform lead because its differentiation has already produced results in two human settings. CRISPR Therapeutics still owns the broader and more valuable position today.
If you want more recent data on this point, please see our latest biotechnology market report.
Which gene-editing startup has the most financial firepower?
CRISPR Therapeutics has the strongest balance sheet by a large margin, with about twice Beam’s cash and more than three times Intellia’s pro forma resources.
CRISPR Therapeutics ended the first quarter with $2.44 billion after issuing convertible notes. Beam had $1.2 billion and expects its runway to reach mid-2029. Intellia reported $517 million before adding roughly $207 million of gross proceeds from its spring equity raise, bringing pro forma resources to about $724 million.
The financial distance is substantial because late-stage gene-editing development is expensive. Beam can prepare a sickle-cell filing and run a pivotal AATD cohort without immediately choosing between them. Intellia can finance a possible lonvo-z launch and continue the restarted nex-z trials. CRISPR Therapeutics can absorb setbacks across several programs.
Smaller competitors have less room for error. Precision had about $126 million, Prime about $149 million, Caribou $119 million and Metagenomi about $140 million in their latest reports. Editas improved its position by raising $125 million upfront in a public offering. Scribe is also trying to raise public capital as STX-1150 enters clinical development.
Funding cannot rescue a weak product, but a thin balance sheet can stop a promising program before its decisive trial.
| Startup | Latest reported or pro forma cash | Relative to CRISPR Therapeutics | Practical implication |
|---|---|---|---|
| CRISPR Therapeutics | $2.44B | 100% | Can fund several major programs and absorb setbacks |
| Beam Therapeutics | $1.20B | 49% | Can pursue two late-stage paths together |
| Intellia Therapeutics | About $724M | 30% | Enough for filing, launch preparation and resumed Phase 3 work |
| Prime Medicine | About $149M | 6% | Must stay selective and use partners carefully |
| Metagenomi Therapeutics | About $140M | 6% | Enough to reach first clinical entry, with limited cushion |
| Precision BioSciences | About $126M | 5% | Human progress is strong relative to capital, but risk remains high |
| Editas Medicine | Cash plus $125M new gross proceeds | N/A | Financing buys time for EDIT-401 to reach humans |
| Caribou Biosciences | $119M | 5% | Does not fully cover the planned pivotal program |
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Which gene-editing startup has the strongest momentum right now?
Intellia has the strongest momentum today, Beam is moving almost as quickly across more programs, and Scribe has become the most interesting early-stage mover.
Intellia changed its competitive position in a few months. It reported a successful Phase 3 trial, added detailed results showing large reductions in severe and rescue-treated attacks, started a rolling BLA and resumed screening in both nex-z Phase 3 studies after the clinical holds were lifted.
Beam’s progress is broader. Risto-cel data reached a major medical journal, the company kept a possible year-end submission on the table, BEAM-302 moved toward a pivotal cohort, and BEAM-304 received FDA clearance for a first clinical study.
Precision added biopsy evidence that its HBV editor was reaching cccDNA. Prime received RMAT designation and cleared its first in vivo Wilson-disease study in New Zealand. Arbor gained European orphan designation after beginning its Phase 1/2 study. Tessera received Fast Track and orphan status for TSRA-196.
Scribe also deserves attention. The company secured clearance for a 64-person first-in-human study of STX-1150, won more than $25 million from California’s stem-cell agency and filed to go public. STX-1150 aims to lower LDL cholesterol for years by silencing PCSK9 without permanently changing the DNA sequence.
CRISPR Therapeutics is advancing through CASGEVY adoption and its in vivo pipeline, but Intellia has changed its competitive position more sharply lately.
Which gene-editing startups are actually ahead?
CRISPR Therapeutics leads overall, Intellia is the only company close enough to take first place soon, and Beam is the strongest long-term platform challenger.
We weight approval, repeatable clinical evidence and commercial execution most heavily. Platform elegance, funding and partnerships matter, but they cannot compensate indefinitely for missing clinical proof.
CRISPR Therapeutics has completed the whole cycle once. CASGEVY is approved across several markets, reimbursed, generating revenue and moving a growing number of patients through treatment. The company also has the largest balance sheet and a wider internal pipeline than it had when CASGEVY was approved. Vertex receives 60% of the economics and runs commercialization, but CRISPR Therapeutics still owns the strongest body of proof.
Intellia sits much closer than a conventional second-place biotech. Lonvo-z has successful randomized Phase 3 data, an active rolling BLA and a product design that should scale more easily than an autologous stem-cell therapy. Intellia can take first place if lonvo-z wins approval, launches cleanly and shows durable real-world benefit.
Beam holds third without much debate. Two human programs support the base-editing platform, the company has enough cash to pursue both late-stage paths, and a third liver program has entered the clinic. Risto-cel reaching submission and BEAM-302 entering pivotal development would move Beam closer to the top two.
Precision ranks fourth because its human HBV result is unusually specific and it has a second in vivo program entering patients. Caribou ranks fifth because vispa-cel has meaningful scale and a Phase 3 plan, though safety and financing remain heavy constraints. Prime ranks sixth because the first human prime-editing result is exceptional but rests on two patients.
The lower half remains fluid. Arbor is already testing its editor in people. Scribe has just crossed into the clinic. Tessera has clinical clearance but no disclosed patient results. Editas has fresh financing after a difficult reset. Metagenomi and Mammoth still need human therapeutic evidence.
CRISPR Therapeutics leads the market that exists today. Intellia leads the race to commercial in vivo editing. Beam has the best chance to own the next generation of the technology.
| Rank | Startup | Why it ranks here | What could change the ranking |
|---|---|---|---|
| 1 | CRISPR Therapeutics | Only company here with an approved, reimbursed and revenue-producing gene-editing medicine; deepest commercial proof and strongest balance sheet | Slow CASGEVY uptake or weak follow-on programs could let Intellia pass it |
| 2 | Intellia Therapeutics | Successful randomized Phase 3 in vivo trial, rolling BLA and the easiest leading product to scale | A clean approval and launch could move Intellia to first; safety or review problems could push it back |
| 3 | Beam Therapeutics | Best validated next-generation platform, two important human datasets and ample capital | Risto-cel submission plus successful BEAM-302 pivotal execution could create a top-two company |
| 4 | Precision BioSciences | Direct human evidence against HBV cccDNA and two clinical in vivo programs | Durable functional-cure evidence in hepatitis B would move Precision sharply higher |
| 5 | Caribou Biosciences | Strongest gene-edited off-the-shelf CAR-T dataset and a credible Phase 3 design | Full financing and safer durable Phase 3 results would support a higher rank |
| 6 | Prime Medicine | First convincing human prime-editing result and a very broad technical ceiling | More patients and successful in vivo liver data are needed |
| 7 | Arbor Biotechnologies | Already dosing a compact in vivo editor, with regulatory designations and Chiesi support | Convincing pharmacodynamic or efficacy data could move Arbor into the upper group |
| 8 | Scribe Therapeutics | First clinical study cleared, a differentiated reversible-silencing approach and fresh funding momentum | Human LDL reduction with a clean safety profile would change the ranking quickly |
| 9 | Tessera Therapeutics | Ambitious Gene Writing platform and a cleared AATD study | The first treated-patient data will decide whether the platform can move beyond promise |
| 10 | Editas Medicine | Valuable editing know-how, fresh capital and a rebuilt cardiovascular program | EDIT-401 needs to enter humans and reproduce its preclinical effect |
| 11 | Metagenomi Therapeutics | Broad editor-discovery engine and a hemophilia program approaching an IND | Human factor VIII production would give the company its first decisive proof |
| 12 | Mammoth Biosciences | Ultracompact editors could unlock difficult tissues, with major pharmaceutical validation | A therapeutic program must enter humans before Mammoth can rank with clinical-stage rivals |
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time
OUR METHODOLOGY
This analysis compares 12 independent companies whose core business is developing gene-editing medicines for people. We include conventional CRISPR, base editing, prime editing, compact nucleases, Gene Writing, epigenetic silencing and gene-edited cell therapies when the editing technology is central to the product.
We broke the leadership question into separate tests: clinical evidence, regulatory progress, commercial execution, in vivo leadership, platform depth, financial firepower, recent momentum and the probability of the next approval. We then looked at how consistently each company performed across those dimensions rather than letting one headline decide the ranking.
Approval, randomized clinical evidence, repeatable human efficacy and real commercial use received the most weight. Small open-label studies, biomarker changes, regulatory designations and preclinical results still count, but they do not carry the same force. Platform range and scientific elegance were treated as advantages only when there was evidence that the technology could be delivered, manufactured and made to work in people.
For clinical comparisons, we used the most mature disclosed dataset for each company and considered patient count, study design, endpoint quality, durability, safety and how directly the measurement reflected the disease mechanism. That is why a small liver-biopsy dataset can sometimes be more informative than a larger study built around a downstream marker.
Commercial leadership was assessed separately from scientific leadership. CASGEVY’s approvals, reimbursement coverage, treatment-centre network, patient starts and reported revenue were treated as evidence of a functioning product business, while licensing revenue and partnership milestones were not treated as proof of repeatable patient demand.
Financial comparisons use the latest reported cash, cash equivalents and marketable securities, adjusted for disclosed financing completed after the reporting date when the article explicitly describes the figure as pro forma. Historical funding totals are included for context, but they are not substitutes for current runway.
We prioritized recent company filings, trial disclosures, regulatory records and peer-reviewed or major medical-conference data. Older milestones were used mainly to establish long-term execution. The ranking is a current judgment, not a permanent view; a clean approval, a pivotal failure or a serious safety event could change it quickly.
Key sources include the official company and investor materials from CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, Precision BioSciences, Caribou Biosciences, Prime Medicine, Arbor Biotechnologies, Tessera Therapeutics, Scribe Therapeutics, Editas Medicine, Metagenomi and Mammoth Biosciences.
Regulatory and independent checks came from the U.S. Food and Drug Administration, the European Medicines Agency, ClinicalTrials.gov, SEC filings, and published or presented evidence from Nature Biotechnology, The New England Journal of Medicine, The Lancet, the American Society of Hematology and the European Association for the Study of the Liver. Vertex materials were used for CASGEVY commercialization and access data.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Who will deliver the first in-body CRISPR cure?
- RNA medicines: which startup is ahead?
- Which startup looks most promising in reversing cellular aging?
